| 7.69 0 (0%) | 07-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.29 | 1-year : | 9.72 |
| Resists | First : | 7.95 | Second : | 8.32 |
| Pivot price | 7.66 |
|||
| Supports | First : | 7.35 | Second : | 6.11 |
| MAs | MA(5) : | 7.55 |
MA(20) : | 7.77 |
| MA(100) : | 8.21 |
MA(250) : | 14.11 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 35.5 |
D(3) : | 23.3 |
| RSI | RSI(14): 44.7 | |||
| 52-week | High : | 33.83 | Low : | 5.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TIL ] has closed below upper band by 46.6%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.82 - 7.86 | 7.86 - 7.9 |
| Low: | 7.51 - 7.56 | 7.56 - 7.6 |
| Close: | 7.62 - 7.7 | 7.7 - 7.77 |
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.
Mon, 29 Jun 2026
Price to sales forward of Instil Bio, Inc. – NASDAQ:TIL - TradingView
Wed, 17 Jun 2026
Instil Bio Inc (TIL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fri, 12 Jun 2026
Instil Bio (TIL) director Gwendolyn Binder awarded 6,500 stock options at $7.93 - Stock Titan
Thu, 11 Jun 2026
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
Sun, 31 May 2026
TIL - Instil Bio Inc Stock Price and Quote - Finviz
Fri, 15 May 2026
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 62.2 (%) |
| Shares Short | 234 (K) |
| Shares Short P.Month | 231 (K) |
| EPS | -7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.79 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -12.7 % |
| Return on Equity (ttm) | -37.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -1.1 |
| PEG Ratio | 0 |
| Price to Book value | 0.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|